1. Home
  2. Studies
  3. Where the German Pharmaceutical Industry Sources its Intermediate Inputs: An International Comparison
Jasmina Kirchhoff IW-Trends No. 1 9. February 2022 Where the German Pharmaceutical Industry Sources its Intermediate Inputs: An International Comparison

The Corona pandemic has led to increasing demands for the reshoring of pharmaceutical production back to Germany. A strategic dependence on non-European active ingredient and drug manufacturers is cited as an argument.

Download PDF
An International Comparison
Jasmina Kirchhoff IW-Trends No. 1 9. February 2022

Where the German Pharmaceutical Industry Sources its Intermediate Inputs: An International Comparison

Download PDF Quote

Copy the information

The link was added to your clipboard!

Share this article:

or copy the following link:

The link was added to your clipboard!

German Economic Institute (IW) German Economic Institute (IW)

The Corona pandemic has led to increasing demands for the reshoring of pharmaceutical production back to Germany. A strategic dependence on non-European active ingredient and drug manufacturers is cited as an argument.

However, the German pharmaceutical industry sources most of its medicinal and chemical inputs either domestically or from other European countries. A similarly regional supply structure is to be found in the pharmaceutical and chemical sectors of those countries which supply the majority of intermediate inputs to Germany’s pharmaceutical industry, with those from China and India playing only a subordinate role. There is thus no evidence that German pharmaceutical production is predominantly dependent on these two Asian nations. However, since intermediate inputs are recorded by value, and prices for generic medicines and their active ingredients are much lower than those for innovative products, it is possible that despite China's small share of intermediate input purchases there may be a dependency in the case of certain individual generics. Nonetheless, a strategic boost to pharmaceutical production in Germany is scarcely to be achieved by expanding generic production. What is needed is rather a well-coordinated package of policy measures designed to encourage locally based firms to maintain and make long-term investments in their domestic production facilities and to promote the development of new innovative production. Such a course also pays off in terms of security of supply, since the patented innovative medicines of today are the generics of tomorrow.

Content element with id 10503
Download PDF
An International Comparison
Jasmina Kirchhoff IW-Trends No. 1 9. February 2022

Where the German Pharmaceutical Industry Sources its Intermediate Inputs: An International Comparison

Download PDF Quote

Copy the information

The link was added to your clipboard!

German Economic Institute (IW) German Economic Institute (IW)

Share this article:

or copy the following link:

The link was added to your clipboard!

More on the topic

Read the article
New attempt to harmonise corporate taxation in the EU
Tobias Hentze / Samina Sultan IW-Report No. 7 3. February 2023

New attempt to harmonise corporate taxation in the EU

In the course of 2023, the European Commission plans to present a proposal for a new corporate tax system under the title "Business in Europe: Framework for Income Taxation (BEFIT)".

IW

Read the article
Martin Beznoska / Björn Kauder / Finn Arnd Wendland IW-Trends No. 4 25. January 2023

Factors Influencing the Decentralised Energy Transition in North Rhine-Westphalia

North Rhine-Westphalia (NRW), the most populous of Germany’s sixteen states and an industrial heartland, is a particular focus of the energy transition. Despite considerable progress in expanding the use of renewable energy, NRW still lags far behind other ...

IW

More about this topic

Content element with id 8880 Content element with id 9713